Abstract
Statins have been reported to reduce the risk and be of benefit in the treatment of Alzheimers disease (AD). Individuals enrolling in the randomized controlled trial testing two anti-inflammatory agents for primary prevention of AD (Alzheimers Disease Anti-inflammatory Prevention Trial; ADAPT) were allowed the elective use of statins. Our objective was to assess whether statin use is associated with reduced risk of incident AD among ADAPT participants. In primary ADAPT study , participants were assessed annually for cholesterol levels and cognitive status. If impairment in cognition was noted, a dementia evaluation was performed. Onset of mild cognitive impairment (MCI) or AD was taken as the date of this evaluation. Time-to-onset was analyzed in six-month intervals following enrollment. Without knowledge of primary treatment assignment in ADAPT, participants were grouped by their self-reported use of lipid-lowering agents (LLA). In the current ancillary ADAPT study we found that elective statin use was associated with significantly reduced risk of incident AD after adjustment for age, gender, education and Apolipoprotein E (ApoE) genotype. The findings were similar when comparing all LLA use (statin and non-statin LLA) to non-LLA use. Cholesterol levels were lower among statin users compared with non-LLA users, but the MMSE scores were equivalent. The data suggest that statin therapy may be of benefit in reducing the risk of AD.
Keywords: Statin, Alzheimer's disease (AD)., anti-inflammatory agents, cholesterol levels, dementia, lipid-lowering, agents (LLA)
Current Alzheimer Research
Title: Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort
Volume: 5 Issue: 4
Author(s): D. Larry Sparks, Richard J. Kryscio, Marwan N. Sabbagh, Donald J. Connor, Lisa M. Sparks and Carolyn Liebsack
Affiliation:
Keywords: Statin, Alzheimer's disease (AD)., anti-inflammatory agents, cholesterol levels, dementia, lipid-lowering, agents (LLA)
Abstract: Statins have been reported to reduce the risk and be of benefit in the treatment of Alzheimers disease (AD). Individuals enrolling in the randomized controlled trial testing two anti-inflammatory agents for primary prevention of AD (Alzheimers Disease Anti-inflammatory Prevention Trial; ADAPT) were allowed the elective use of statins. Our objective was to assess whether statin use is associated with reduced risk of incident AD among ADAPT participants. In primary ADAPT study , participants were assessed annually for cholesterol levels and cognitive status. If impairment in cognition was noted, a dementia evaluation was performed. Onset of mild cognitive impairment (MCI) or AD was taken as the date of this evaluation. Time-to-onset was analyzed in six-month intervals following enrollment. Without knowledge of primary treatment assignment in ADAPT, participants were grouped by their self-reported use of lipid-lowering agents (LLA). In the current ancillary ADAPT study we found that elective statin use was associated with significantly reduced risk of incident AD after adjustment for age, gender, education and Apolipoprotein E (ApoE) genotype. The findings were similar when comparing all LLA use (statin and non-statin LLA) to non-LLA use. Cholesterol levels were lower among statin users compared with non-LLA users, but the MMSE scores were equivalent. The data suggest that statin therapy may be of benefit in reducing the risk of AD.
Export Options
About this article
Cite this article as:
Sparks Larry D., Kryscio J. Richard, Sabbagh N. Marwan, Connor J. Donald, Sparks M. Lisa and Liebsack Carolyn, Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort, Current Alzheimer Research 2008; 5 (4) . https://dx.doi.org/10.2174/156720508785132316
DOI https://dx.doi.org/10.2174/156720508785132316 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular Mechanisms of the Protective Effect of Polyphenols on the Neurovascular Unit in Strokes
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches
Current Pharmaceutical Biotechnology The Application of Proteomics in Neurology
Current Proteomics Lecithin (Phosphatidylcholine): Healthy Dietary Supplement or Dangerous Toxin?
The Natural Products Journal Novel Circular, Cyclic and Acyclic ψ(CH2O) Containing Peptide Inhibitors of SKI- 1/S1P: Synthesis, Kinetic and Biochemical Evaluations
Current Medicinal Chemistry Molecular and Cellular Mechanisms for Alzheimers Disease:Understanding APP Metabolism
Current Molecular Medicine The Importance of Citicoline in Combined Treatment in Dementia: What did the Citimem Study Teach us?
Reviews on Recent Clinical Trials Berberine Nanoencapsulation Attenuates Hallmarks of Scoplomine Induced Alzheimer's-Like Disease in Rats
Current Reviews in Clinical and Experimental Pharmacology Neurobiological Influences on Recovery from Traumatic Brain Injury: The Role of Genetic Polymorphisms
Current Pharmaceutical Design Computer Aided Drug Design Studies in the Discovery of Secondary Metabolites Targeted Against Age-Related Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Novel Automated Method for the Detection of White Matter Hyperintensities in Brain Multispectral MR Images
Current Medical Imaging Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials Melatonin Receptor as a Drug Target for Neuroprotection
Current Molecular Pharmacology Seeing Early Signs of Alzheimer's Disease Through the Lens of the Eye
Current Alzheimer Research Functional Neurochemistry of Alzheimers Disease
Current Pharmaceutical Design Dehydroepiandrosterone Treatment Alters Lipid/Phospholipid Profiles of Rat Brain and Liver Mitochondria
Current Neurovascular Research Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research Clinical Features and Disease Damage Risk Factors in an Egyptian SLE Cohort: A Multicenter Study
Current Rheumatology Reviews The MMP-2/TIMP-2 System in Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Brutons Tyrosine Kinase as a New Therapeutic Target
Anti-Cancer Agents in Medicinal Chemistry